This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Metuchen Pharmaceuticals LLC

Drug Names(s): TA-1790, avanafil, Spedra (EU), Zepeed (South Korea)

Description: Avanafil is a highly selective, orally administered phosphodiesterase type 5 (PDE5)inhibitor being developed to treat erectile dysfunction. It has a rapid onset of action (Tmax ~35 minutes), which is hoped to lead to quicker efficacy, but may be hampered by a short half life (1.5 hours).

Deal Structure: Vivus and Mitsubishi Tanabe
In March 2001, Vivus licensed Tanabe Seiyaku's Avanafil for the oral and local treatment of maleand female sexual dysfunction. Under the terms of the agreement, Vivus has acquired worldwide rights, except Japan, China and certain Pacific Rim countries, to develop and commercialize Avanafil. Tanabe will be responsible for manufacturing Avanafil. In exchange, Tanabe has received an undisclosed up-front payment and will receive additional payments based on certain development, regulatory and sales milestones. In addition, Tanabe will receive royalties on net sales of products containing Avanafil.

In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku and Mitsubishi Pharma Corporation.

In August 2012, Vivus entered into an amendment to the Agreement with Mitsubishi Tanabe which, among other matters, allows the Company to manufacture the active pharmaceutical ingredient (API) and tablets for STENDRA...See full deal structure in Biomedtracker

Partners: Mitsubishi Tanabe Pharma Corporation The Menarini Group Vivus, Inc. Sanofi

Stendra News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug